Visceral involvement as initial manifestation of AIDS‐related Kaposi's sarcoma

2021 ◽  
Vol 57 (3) ◽  
pp. 453-453
Author(s):  
Rita V Carvalho ◽  
Teresa Campos
Keyword(s):  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Initial Manifestation ◽  
Visceral Involvement

Differential Impact of Combination Antiretroviral Therapy in Preventing Kaposi's Sarcoma With and Without Visceral Involvement

2006 ◽  
Vol 24 (21) ◽  
pp. 3408-3414 ◽  
Author(s):  
Sophie Grabar ◽  
Bruno Abraham ◽  
Aba Mahamat ◽  
Pascal Del Giudice ◽  
Eric Rosenthal ◽  
...  
Keyword(s):  
Kaposi's Sarcoma ◽  
Proportional Hazards ◽  
Specific Effect ◽  
Kaposi’S Sarcoma ◽  
Cox Proportional Hazards ◽  
Nucleoside Analog ◽  
Large Hospital ◽  
Visceral Involvement ◽  
The Impact

Purpose To study the impact of different potent combined antiretroviral treatment (cART) on the incidence of HIV-associated Kaposi's sarcoma (KS) with and without visceral involvement. Patients and Methods Patients were selected from the French Hospital Database on HIV, a large hospital cohort. The risk of KS was estimated by using Cox proportional hazards models adjusting for age, the CD4 cell nadir, the HIV exposure category, prior AIDS, cART, and the type of cART regimen. cART regimens were distinguished according to whether they contained protease inhibitor (PI), non-nucleoside analog (NNRTI), both, or only nucleoside analog (NRTI). Separate analyzes were conducted according to the initial visceral involvement of KS. Results Among the 54,999 patients included in this study (182,756 person-years of follow-up), 1,634 patients were diagnosed with KS during follow-up, of whom 421 had visceral involvement at diagnosis. The KS incidence rate fell from 32 per 1,000 person-years in 1993 to 1994 to 3 per 1,000 person-years after 1999. PI-containing and NNRTI-containing cART regimens were associated with similar reductions in the risk of KS (hazard ratio, 0.68; 95%CI, 0.61 to 0.75; HR, 0.62; 95% CI, 0.54 to 0.71, respectively). The risk of visceral KS fell more strongly than the risk of cutaneous KS (> 50% and < 30%, respectively). Conclusion The incidence of KS, and especially visceral KS, has fallen sharply since the advent of cART. This effect is likely due to immune restoration rather than to a specific effect on the tumoral process, as PI-containing and NNRTI-containing regimens had similar preventive efficacy.

scholarly journals Quasi-Complete Response of Classic Kaposi’s Sarcoma Treated with Weekly Paclitaxel

2013 ◽  
Vol 2013 ◽  
pp. 1-3 ◽  
Author(s):  
Zineb Benbrahim ◽  
Samia Arifi ◽  
Hafida Benhammane ◽  
Kaoutar Inani ◽  
Salim Gallouj ◽  
...  
Keyword(s):  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Complete Response ◽  
Skin Lesions ◽  
Weekly Paclitaxel ◽  
Classical Type ◽  
Prior Therapy ◽  
Visceral Involvement ◽  
First Line Therapy ◽  
Late Stages

Classic Kaposi’s sarcoma (CKS) is a subtype that traditionally occurs in elderly HIV-negative males of Mediterranean origin. Patients with CKS characteristically present with skin lesions in the distal extremities. Involvement of the viscera is uncommon but may occur in the late stages of the disease. Patients with extensive KS can be treated with systemic chemotherapy. A number of drugs approved for treatment of AIDS-associated KS, especially Paclitaxel, have activity against CKS after failure of prior therapy. We report a patient treated with weekly Paclitaxel, as initial chemotherapy, for CKS presenting with multiple visceral involvement and having a contraindication for Bleomycin. The patient had quasi-complete response after three months of chemotherapy suggesting that weekly Paclitaxel might be effective as a first-line therapy for classical type KS with visceral involvement.

scholarly journals Conjunctival Kaposi’s sarcoma as the initial manifestation of acquired inmunodeficiency syndrome

2013 ◽  
Vol 5 (2) ◽  
pp. 265-267 ◽  
Author(s):  
Carlos Izquierdo Rodriguez ◽  
JM Cordova
Keyword(s):  
Rare Case ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Drug Addict ◽  
Initial Manifestation ◽  
Acquired Immunodeficiency ◽  
Immunodeficiency Syndrome ◽  
Hiv Seropositive ◽  
Conjunctival Lesion ◽  
Parenteral Drug

Introduction: Kaposi’s sarcoma is a common neoplasm in patients with acquired immunodeficiency syndrome (AIDS). Its presentation as an initial manifestation of AIDS is very rare . Objective: To report a rare case with Kaposi’s’s sarcoma as an initial manifestation of AIDS. Case: We report the case of a 37-year-old man who was a parenteral drug addict, HIV seropositive and was not under any treatment with a conjunctival lesion which was diagnosed as Kaposi’s sarcoma after surgical resection. Conjunctival Kaposi’s sarcoma is present frequently in HIV patients and lesions may be mistaken with other conjunctival lesions. Nepal J Ophthalmol 2013; 5(10): 265-267 DOI: http://dx.doi.org/10.3126/nepjoph.v5i2.8741

Kaposi's sarcoma with visceral involvement after intraarticular and epidural injections of corticosteroids

1993 ◽  
Vol 29 (5) ◽  
pp. 890-894 ◽  
Author(s):  
Akiva Trattner ◽  
Emmilia Hodak ◽  
Michael David ◽  
Amy Neeman ◽  
Miriam Sandbank
Keyword(s):  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Epidural Injections ◽  
Visceral Involvement

scholarly journals S1735 A Rare Case of Immunosuppression-Induced Kaposi’s Sarcoma With Dermatologic and Visceral Involvement

2021 ◽  
Vol 116 (1) ◽  
pp. S770-S771
Author(s):  
Michelle Shah ◽  
Gres Karim ◽  
Neelesh Rastogi ◽  
Dewan Giri ◽  
Amreen Dinani
Keyword(s):  
Rare Case ◽  
Kaposi's Sarcoma ◽  
Kaposi’S Sarcoma ◽  
Visceral Involvement
Sign in / Sign up

Export Citation Format

Share Document